GREER® Laboratories, Inc. Completes Deal with Ares Life Sciences
News May 01, 2013
“We are pleased that this transaction has been finalized, and we renew our commitment to allergy immunotherapy, our customers and their patients, ensuring that we will continue to deliver quality allergy immunotherapy products, services and customer support,” shares John G. Roby, GREER President and CEO.
GREER’s clinical development programs are focused on the company’s investigational sublingual allergy immunotherapy liquid (SAIL™). The company recently completed a successful Phase III study evaluating the efficacy and safety of GREER® SAIL™ as a treatment for adults with short ragweed allergies. Sublingual allergy immunotherapy (SLIT) is a method of allergy immunotherapy that delivers the same liquid allergenic extract approved for subcutaneous injections, but it is administered under the tongue. SLIT has been widely accepted as a safe, effective treatment for allergic rhinitis in Europe for years.1 However, SLIT is currently investigational in the United States.
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE